Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive ma...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Yoshimoto, Takayuki, Mizoguchi, Izuru, Katagiri, Seiichiro, Tauchi, Tetsuzo, Furusawa, Jun-ichi, Chiba, Yukino, Mizuguchi, Junichiro, Ohyashiki, Junko H, Ohyashiki, Kazuma
Formato: Artigo
Idioma:Inglês
Publicado: Landes Bioscience 2014
Assuntos:
Author's View
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4091524/
https://ncbi.nlm.nih.gov/pubmed/25057448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.28861
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares